PainReform

PRFXPhase 3

PainReform is dedicated to developing innovative, non-opioid pain management solutions by leveraging its proprietary extended-release drug delivery platform. Its primary mission is to address the significant unmet need for effective, long-lasting post-operative analgesia, thereby reducing reliance on systemic opioids and their associated risks. The company's most advanced candidate, PRF-110, has demonstrated promising results in clinical trials for bunionectomy and hernia repair. PainReform's strategy centers on advancing its pipeline through clinical development and seeking strategic partnerships for commercialization.

Market Cap

$1.8M

Employees

11-50

Focus

Biotech

AI Company Overview

Technology Platform

Proprietary extended-release drug delivery platform designed to reformulate established local anesthetics (like ropivacaine) into polymer-based formulations that provide controlled, sustained release at a surgical site for up to 72 hours.

Pipeline Snapshot

4 drugs in pipeline, 1 in Phase 3

Drug	Indication	Stage
Ropivacaine	Bunion	Phase 3
PRF110- oily solution (Ropivacaine)	Post Operative Pain	Phase 2
PRF110	Post Operative Pain	Phase 2
PRF-108 + Placebo + Ropivacaine + PRF-110	Pain	Phase 1/2

Opportunities

The global shift away from opioid-based pain management creates a massive opportunity for effective, non-opioid alternatives like PRF-110.

Expanding the clinical program of PRF-110 into additional common surgical procedures (e.g., orthopedic, abdominal) could significantly increase its addressable market.

Forming a strategic partnership with an established commercial player in the hospital/surgical space would provide the resources needed for successful market penetration and validation.

Risk Factors

The company faces significant clinical and regulatory risk, as failure in ongoing or future trials would be catastrophic.

As a pre-revenue company with a single lead asset, it is highly dependent on raising additional capital in volatile markets.

Upon any potential approval, PRF-110 would face intense competition from well-funded, marketed products with established sales forces and formulary positions.

Competitive Landscape

PainReform's main competitors are Pacira BioSciences (Exparel) and Heron Therapeutics (Zynrelef), which have first-mover advantage in the extended-release local anesthetic market. PainReform aims to differentiate PRF-110 through the use of ropivacaine (perceived safety advantage) and its proprietary delivery technology, seeking to demonstrate prolonged and effective analgesia to capture market share in targeted surgical segments.